Laprophan, one of Morocco’s leading pharmaceutical firms, is taking a major step forward in its international growth strategy with the planned acquisition of controlling stakes in three European companies. In a joint deal with Swiss investor Piero Luigi Umberto Poli, the group will acquire 60% ownership in Pian Holding BV, Double-e Pharma Limited, and Rivopharm Limited—marking a strategic move into the generics market.
The acquisition reflects Laprophan’s growing ambition to establish a stronger footprint in Europe. The company will act through its Luxembourg-based subsidiary, Europhan Europe SA, to purchase shares in Dutch holding company Pian Holding, while directly acquiring stakes in the two Ireland-based firms. All three targeted companies are involved in the generic pharmaceuticals sector, with a particular focus on product registration and regulatory compliance within the European Union.
Pian Holding, headquartered in the Netherlands, operates as an investment vehicle, while Double-e Pharma and Rivopharm focus on navigating the regulatory landscape for drug approvals across European markets. The addition of these companies aligns with Laprophan’s broader strategy of reinforcing its presence along the entire pharmaceutical value chain, from research and development to distribution.
The deal also underscores the continued involvement of Piero Poli, a long-standing shareholder in the businesses. Following the transaction, Poli will retain a significant minority stake and share governance with Laprophan, ensuring continuity and a balanced leadership structure.
This latest move builds on Laprophan’s recent establishment of Europhan Europe, a clear signal that the Moroccan group is looking to structure and scale its European operations more aggressively. The acquisition represents more than just market expansion—it’s a consolidation of expertise, regulatory access, and operational capacity in one of the most competitive pharmaceutical regions in the world.
